Virtual Incision secures $20M to test its gastrointestinal surgery mini-robot

surgical robotics
Lincoln, Nebraska-based Virtual Incision is also developing specialty robots for hernia repair, gallbladder removal, gastric bypass, antireflux surgery and other abdominal procedures. (Virtual Incision)

Virtual Incision raised $20 million for the development of its miniaturized surgical robot to help support its regulatory programs and clinical testing. 

The company recently submitted its initial filings with the FDA, seeking an investigational device exemption that will allow it to begin confirmatory studies in colon resection surgeries at a number of U.S. sites.

The MIRA robot is designed to allow surgeons to perform assisted, minimally invasive surgeries in a hospital or center without the need for dedicated spaces or heavy infrastructure. Weighing only two pounds, the small surgical robot can be moved and set up in any room. 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We designed the MIRA Surgical Robotic Platform with the fundamental understanding that minimally invasive procedures offer tremendous benefits to patients,” President and CEO John Murphy said in a statement (PDF).

“We believe our portable and affordable abdominal robot has the potential to bring these benefits to many more patients,” Murphy said. “The planned IDE clinical study of MIRA is the critical next step for the company.”

RELATED: Virtual Incision reels in $18M in series B round to support its surgical robotics

Virtual Incision’s latest series B+ financing round was led by returning backer Bluestem Capital with additional participation from PrairieGold Venture Partners, Genesis Innovation Group and other affiliated investors. A 2017 series B round previously raised $18 million in 2017. 

The Lincoln, Nebraska-based company describes colorectal and lower gastrointestinal procedures as among the fastest-growing surgical segments in the U.S., with over 400,000 colon resections being performed annually. Typically, the colectomy procedure involves a large, open incision plus long hospital stays and rehabilitation time. 

“Beyond our initial device design for colon resection, Virtual Incision has begun developing a family of procedure-specific mini-robots for additional operations such as hernia repair, gallbladder removal and others, potentially enabling millions more surgical procedures each year,” said Shane Farritor, Virtual Incision’s co-founder and chief technology officer.

This includes specialty hardware for antireflux surgery, splenectomy, adrenalectomy, gastric sleeve, gastric bypass, hysterectomy and hepato-pancreato-biliary procedures.

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

Kintai Therapeutics' anti-obesity candidate KTX-0200 showed sustained weight loss and improved glucose control and liver health in rodents.

The respiratory care company Vyaire Medical has brought on a new CEO, Gaurav Agarwal, following a year of new product launches.